Last reviewed · How we verify
LEO 90100
LEO 90100 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.
LEO 90100 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | LEO 90100 |
|---|---|
| Also known as | calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) |
| Sponsor | LEO Pharma |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting phosphodiesterase 4, LEO 90100 increases intracellular cAMP levels in immune and inflammatory cells, suppressing the release of pro-inflammatory mediators such as TNF-α and IL-23. This mechanism reduces skin inflammation and is designed for topical treatment of inflammatory skin conditions.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Application site irritation
- Application site pain
- Headache
Key clinical trials
- A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (PHASE3)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis (PHASE2)
- Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris (PHASE2)
- Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 90100 CI brief — competitive landscape report
- LEO 90100 updates RSS · CI watch RSS
- LEO Pharma portfolio CI